retatrutide trial news today Retatrutide, a new weight loss drug not available on the market yet, is showing promising results in trials. @DrLaPook explains it’s doing much more than what current medications can 🚨 Retatrutide TRIUMPH-1 Phase 3

The copper ion itself serves as a cofactor for lysyl oxidase, the enzyme responsible for collagen and elastin cross-linking, meaning GHK-Cu both stimulates production of new structural proteins and ensures they are properly stabilized

Your genetic predispositions don't change your injection frequency, but they do inform your personalized dose pathway

Are comfortable with limited regulatory oversight

Lieberman OJ, Sulzer D

The menopausal decline in estrogen triggers a shift in fat deposition, with a significant shift to storing fat centrally around the organs

When cytoplasmic concentrations of neurotransmitters rise dangerously high, TAAR1 activates G-protein-dependent signaling pathways that recruit intracellular kinases, including protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII) (Underhill et al., 2020)